Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation.

Randall C Starling,Brian Armstrong,Nancy D Bridges,Howard Eisen,Michael M Givertz,Abdallah G Kfoury,Jon Kobashigawa,David Ikle,Yvonne Morrison,Sean Pinney,Josef Stehlik,Sudipta Tripathi,Mohamed H Sayegh,Anil Chandraker

Journal of the American College of Cardiology（2019）

引用 35|浏览78

暂无评分

摘要

A marked, unexpected increase in coronary artery PAV with rituximab was observed during the first year in HTX recipients. One-year mortality was not impacted; however, longer-term follow-up and mechanistic explanations are required. (Prevention of Cardiac Allograft Vasculopathy Using Rituximab [Rituxan] Therapy in Cardiac Transplantation; NCT01278745).

查看译文

关键词

coronary artery vasculopathy,immunosuppression,transplant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要